Member Info for researcher1

miavoce, I think £5 would likely do it for AN as well, though will be worth much more over 4 years (my target sell date) - however with our gains we can always buy into the purchaser....

I personally hope any lowball offer like that can be resisted miavoce - the SP will be that on submission of the ovarian application (maybe six months after FDA)

I hope we are not sold for a billion! - that MCAP is less than a year off.

I was just thinking the same Bob - SBTX and OPTI now have similar MCAPs so a 33% stake in SBTX, which will reach £1 before the summer, means all OPTI's IP is being offered FOR FREE!
IP for free! you heard it here first....

enjoying those valuations Dibs and Rich - hard to grasp, aren't they? I know AN has previously stated Angle is targeting an £8B annual market (specific to breast and ovarian cancers - we'll need to wait for full spectrum coverage), so even 10% of that (via P. sales, cartridge replacements, and clinical analysis) is 4X MCAP, and a valuation might be X8. I make that about £16 per share. For starters. Prior to TO bid?

Important to retain a level head, Dibs and Rich. The first opportunity comes via sales of P. devices, and FDA approval will give this a serious push, but it will take time to gain traction. AN has often spoke of a 'targeted £8B liquid biopsy market annually' but this means for other types of cancer too (not yet in front of the FDA). With the addition of ovarian cancer usage - submitted later this year we hope, I can see Angle taking 5% of that total market relatively quickly - that's already revenue 4X MCAP, and a valuation would X8 for starters (this is low). I make that about £16 per share.

thanks Rich - my mistake on the broker comment - not my area of expertise, clearly...

my apologies - OPTI and AGL switched broker on the same day. Angle went to the top of the pile.....

what's great about the news is that there was a tender process - so PWC not only wanted to take on Angle, but must have made their (normally high) fees competitive to win over the client. They can see that train coming down the line. And it's full of delicious gravy.

done, at 29p. Average has shot up to 18p.

imagine what happens when they put an Angle note out to their huge client base...

Never heard then say Q1 Malachi. They are hoping for early Q2, with worst case being late Q2. It depends if further questions are forthcoming I suppose...

trying to get a last few (even though my average is 44) before she flies away.

good sign IMO - ready for the surge...

did a 33% top slice at 35 yesterday, but I'm putting it all back in today. £1 is conservative, sometime in the next 4 months.

this is not even 'par price' yet, let alone with all the developments coming before the summer. AN says in an email that the U.S. investors (who came in at 60p) are wanting an 8-fold return. Interesting. That puts the SP beyond his share option trigger, and the Nasdaq list price.

shift up to the big boys...bodes well...

market likes it, so I like it better now....

I'm a little disappointed personally. Nothing too bad though. Looks well positioned to take market share once the pandemic ends, so 2022 might be SIG's year...

thanks enteleon - very good to have a comprehensive reminder of what, I suppose, we've been taking for granted for a while - though not really - I first got into Angle because of its life-changing potential, and now is the moment. GLA